CURRICULUM VITAE

Maja Hojnik

PERSONAL DETAILS

Full name and title: Maja Hojnik, MD, PhD

Current personal address: 307 N Pennsylvania St, Indianapolis, IN 46204, United States

Mobile phone: Business +1 463 207 6031

E-mail: hojnik_maja@lilly.com

Residency: United States

PROFILE SUMMARY

International medical leader experienced in clinical development and medical affairs in pharmaceutical industry:

- Research experience in immunology, including basic science, translational research, clinical development and real-world-evidence data generation
- Broad spectrum of functional capabilities and experience in medical affairs, including operational leadership and scientific proficiency in the field of rheumatology/immunology
- Due diligence and competitive intelligence experience
- Medical and scientific education/training: MD degree, specialization in Internal Medicine/Rheumatology; PhD degree in Immunology
- Strategically minded, business savvy, proactive, result-oriented and conscientious, with sound medical and scientific background, and proven ability to build and manage high-performing collaborative teams

WORK EXPERIENCE

September 2021 – present (3 years

Associate Vice President, Rheumatology Lead, Immunology Clinical Development, Eli Lilly and Co.

- Overseeing Ph2 - Ph3b/4 clinical development in rheumatology
- Managing a team of medical directors who each supervise a team of clinical research physicians and clinical research scientists
- Acting as rheumatology development strategy lead, including membership in the board of directors for early stage medicinal products

January 2019 – August 2021 (2,5 years)

Medical Director, Rheumatology, Immunology Clinical Development, Eli Lilly and Co.

- Overseeing Ph3 and Ph3b/4 clinical development for ixekizumab and baricitinib in rheumatology (both adult and pediatric)
- Managing a team of clinical research physicians and clinical research scientists
- Leading digital innovation in rheumatology clinical development

- **Achievements through line and cross-functional matrix management:**
- Approval of ixekizumab (Taltz) for the treatment of ankylosing spondylitis (radiographic axSpA) in the United States, European Union (EU) and several countries worldwide
- Approval of ixekizumab (Taltz) for the treatment of non-radiographic axSpA in the United States (first in class of IL-17 inhibitors), EU and several countries worldwide
- License renewal and an additional year of patent exclusivity for Taltz in the EU
- Taltz label enhancement in the EU with head-to-head data versus adalimumab (Humira) in PsA and randomized witdrawal and long-term data in axSpA
- Defended baricitinib label across indications in the European Union as a response to Article 20
- Developed cross-functional clinical and translational recommendations for improvement of SLE clinical trials which will inform private-public LRA initiative with FDA
- Created innovative Ph3 program for novel MoA PD-1 agonist antibody in targeted autoimmune diseases
- Pioneered digital regulatory submission elements with FDA (first in industry)

January 2013 - December 2018 (6 years)

Medical Director, Global Medical Affairs Rheumatology (GMA), AbbVie

- **Global leadership and oversight for research in rheumatology/spondyloarthritis**
- Concept, protocol development and medical oversight for four Ph3b and Ph4 GMA sponsored studies
- Strategic guidance, scientific advice and approval for affiliate research and publications within the respective therapeutic area (TA)
- Medical/scientific input into clinical development programs for immunology assets (specifically Phase 2 and 3 for ABT-122, risankizumab and upadacitinib)
- **Global medical leadership for strategic brand planning and tactical execution**
- Medical expert for the program and content development of scientific exchange and group meetings (scientific symposia, clinical sessions). Products of scope: Humira (adalimumab) and Rinvoq (upadacitinib)
- **Professional engagement with key international external experts in rheumatology**
- Individual and group consulting (advisory boards)

July 2011 - December 2012 (1,5 year)

Associate Medical Director Humira Rheumatology, Central and Eastern Europe (CEE), AbbVie

- Strategic guidance to CEE Affiliate Medical Directors for Humira/Rheumatology associated medical plans
- Leadership, coordination and oversight of regional activities supporting Humira in Rheumatology
- Design and scientific leadership of 4 regional post-marketing observational studies (PMOS) and 2 epidemiological studies that provided data supporting market access in individual countries (also nominated as one of the top 10 programs in the 2014 GMA Celebration of Science contest)

September 2010 - June 2011 (10 months)

Associate Director Area Medical, Central and Eastern Europe (CEE), Abbott

- Development and implementation of regional medical plan and oversight of affiliate plans
- Leadership and oversight of regional and affiliate medical activities, including clinical research, pharmacovigilance and quality assurance
- Medical input to regional commercial plan and initiatives

March 2004 – August 2010 (6 years)

Affiliate Medical Director, Abbott Slovenia

- Established and led affiliate medical department, including medical affairs, regulatory affairs, clinical research, pharmacovigilance and quality assurance
- Secured reimbursement of all approved Abbott medicinal products under fast-track scheme

January 2002 – February 2004 (2 years)

Rheumatology and Oncology Product Specialist, Aventis Pharma, Slovenia

- Medical support to the rheumatology and oncology product portfolio

September 1990 – December 2001 (11 years)

Clinical and Research Fellow, Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia

- Inpatient rheumatology ward
- Outpatient rheumatology service
- Education/training of fellows, residents and students
- Participation in phase II/III clinical trials
- Basic immunology research

EDUCATION

1990 **MD (Dr. med.) degree**
Medical Faculty, University of Ljubljana, Slovenia

1994 **M.Sc. degree in Immunology**
Medical Faculty, University of Ljubljana, Slovenia

1997 **Ph.D. degree in Immunology**
Medical Faculty, University of Ljubljana, Slovenia

2000 **Specialization in Internal Medicine/Rheumatology**
Medical Faculty, Universtity of Ljubljana

ADDITIONAL TRAINING

1992 **Research fellowship** (3 months)
Research Unit of Autoimmune Diseases and Department of Medicine 'B', Sheba Medical Center
(Affiliated to Tel-Aviv University), Tel-Hashomer, Israel
Mentor: Prof. Yehuda Shoenfeld, MD

1993 **Research fellowship** (3 months**)**
Servizio di Immunologia Clinica, Spedali Civili, Brescia, Italy
Mentor: Angela Tincani, MD

1994 - 1995 **Research fellowship** (10 months)
Research Unit of Autoimmune Diseases and Department of Medicine 'B', Sheba Medical Center
(Affiliated to Tel-Aviv University), Tel-Hashomer, Israel
Mentor: Prof. Yehuda Shoenfeld, MD

1996 **Research fellowship** (3 months)
Department of Medicine II and Department of Biochemistry,
Hokkaido University School of Medicine, Sapporo, Japan
Mentors: Prof. Takao Koike, MD and Eiji Matsuura, PhD

1998 **Research fellowship** (3 months)
Department of Medicine II, Hokkaido University School of Medicine, Sapporo, and Department of Biochemistry, Okayama School of Medicine, Okayama, Japan
Mentors: Prof. Takao Koike, MD and Eiji Matsuura, PhD

BIBLIOGRAPHY

1. Stegnar M, Dolžan N, **Hojnik M**, Peternel P. The effect of hypoxia during exercise on release of tissue-

type plasminogen activator (t-PA). **Fibrinolysis 1990**; 4 (Suppl 2): 108-9.

2. **Hojnik M**, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rozman B, Shoenfeld Y. Anticardiolipin antibodies in infections are heterogeneous in their dependency on β_2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. **Lupus 1994**; 3: 515-21.

3. Božič B, **Hojnik M**, Kveder T, Rozman B, Jurčič V, Vizjak A, Ferluga D. Antifosfolipidna protitelesa in antifosfolipidni sindrom (Antiphospholipid antibodies and antiphospholipid syndrome**). Zdrav Vestn 1994**; 63: 311-4.

4. Jurčič V, Ferluga D, Vizjak A, **Hojnik M**, Božič B, Rozman B, Jakša I. Endotelna celica in antiendotelna protitelesa (Endothelial cell and anti-endothelial cell antibodies.) **Zdrav Vestn 1994**; 63: 671-5.

5. Shoenfeld Y, Gilburd B, **Hojnik M**, Damianovich M, Hacham S, Kopolovic Y, Polak-Charcon S, Goldberg I, Afek A, Hun-Chi L, Peter JB. Induction of Goodpasture antibodies to noncollagenous domain (NC1) of type IV collagen in mice by idiotypic manipulation. **Hum Antibodies Hybridomas 1995**; 6: 122-8.

6. **Hojnik M**, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. **Circulation 1996**; 93: 1579-87.

7. Ziporen L, Goldberg I, Arad M, **Hojnik M,** Ordi-Ros J, Afek A, Blank M, Sandbank Y, Vilardell-Tarres M, de Torres I, Weinberger A, Asherson RA, Kopolovic Y, Shoenfeld Y. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. **Lupus 1996**; 5: 196-205.

8. Levy Y, George J, **Hojnic M,** Ehrenfeld M, Lorber M, Bombardieri S, Shoenfeld Y. Comparison of clinical and laboratory parameters for systemic lupus erythematosus activity in Israelis versus Europeans. **Israel J Med Sci 1996;** 32: 100-4.

9. George J, Blank M, Gilburd B, **Hojnik M**, Shenkman B, Tamarin I, Varon D, Matsuura E, Koike T, Shoenfeld Y. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human β_2-glycoprotein I. **Int Immunol 1997**; 9: 913-21.

10. George J, Blank M, **Hojnik M**, Bar-Meir E, Koike T, Matsuura E, Lorber M, Aviram M, Shoenfeld Y. Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS). **Clin Exp Immunol 1997**; 108: 227-33.

11. George J, Gilburd B, **Hojnik M,** Levy Y, Langevitz P, Matsuura E, Koike T, Shoenfeld Y. Target recognition of β_2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. **J Immunol 1998;** 160: 3917-23.

12. Šipek-Dolničar A, **Hojnik M**, Rozman B, Vizjak A, Ferluga D. Small vessel thrombosis without major thrombotic events in systemic lupus erythematosus patients with antiphospholipid syndrome. **Wien Klin Wochenschr 2000**; 15-16: 707-10.

13. Šipek-Dolničar A, **Hojnik M**, Božič B, Vizjak A, Rozman B, Ferluga D. Clinical presentations and vascular histopathology in autopsied patients with with systemic lupus erythematosus and anticardiolipin antibodies**. Clin Exp Rheumatol 2002;** 20: 335-42.

14. Rozman B, Praprotnik S, Logar D, Tomšič M, **Hojnik M**, Kos-Golja M, Accetto R, Dolenc P. Leflunomide and hypertension. **Ann Rheum Dis 2002;** 61: 567-9.

15. Ambrozic A, Avicin T, Ichikawa K, Kveder T, Matsuura E, **Hojnik M**, Atsumi T, Rozman B, Koike T. Anti-β_2-glycoprotein I antibodies in children with atopic dermatitis. **Int Immunol 2002; 14: 823-30.**

16. Ambrozic A, Bozic B, **Hojnik M**, Kveder T, Rozman B. Antiphospholipid antibodies and rheumatoid arthritis. **Ann Rheum Dis 2002; 61: 85-6.**

17. Hočevar A, **Hojnik M**, Praprotnik S, Tomšič M, Kveder T, Rozman B. Parasympathetic nervous system dysfunction in primary Sjögren's syndrome. **Ann Rheum Dis 2003; 62: 702-4.**

18. Šipek-Dolničar A, **Hojnik M,** Rozman B. Bleeding tendency and relapsing small vessel thromboses in a patient with secondary antiphospholipid syndrome. **Clin Exp Rheumatol 2003; 21: 412-3.**

19. Salobir B, Sabovic M, **Hojnik M**, Cucnik S, Kveder T. Anti-beta 2-glycoprotein I antibodies of IgM class are linked to thrombotic disorders in young women without autoimmune disease. **Immunobiology 2007; 212: 193-9.**

20. **Hojnik M**, Dobovišek L, Knez Ž, Ferk P. A synergistic interaction of 17-β-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts. **Biomed Rep. 2015;3: 554-8.**

21. Mandl P, Baranauskaite A, Damjanov N, **Hojnik M**, Kurucz R, Nagy O, Nemec P, Niedermayer D, Perić P, Petranova T, Pille A, Rednic S, Vlad V, Zlnay M, Balint PV. Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countries. **Rheumatol Int 2016; 36: 845-54.**

22. Khobzey K, Liskova I, Szegedi A, Pavlovsky L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M, **Hojnik M**. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice. **Acta Dermatovenerol Alp Pannonica Adriat 2017; 26: 11-4.**

23. Mease PJ, Kavanaugh A, Coates LC, McInnes IB, **Hojnik M**, Zhang Y, Anderson JK, Dorr AP, Gladman DD. Prediction and Benefits of Minimal Disease Activity in Patients With Psoriatic Arthritis and Active Skin Disease in the ADEPT Trial. ***BMJ Open* 2018;8:e019007. doi:10.1136/bmjopen-2017-019007.**

24. Emery P, Burmester GR, Naredo E, Zhou Y, **Hojnik M**, Conaghan PG. Design of a Phase 4 Randomized, Double-Blind, Placebo-Controlled Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels, and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Patients (PREDICTRA). ***BMJ Open* 2018;8:e019007. doi:10.1136/ bmjopen-2017-019007**

25. van der Heijde D, Sieper J, Maksymowych WP, Lambert RG, Chen S, **Hojnik M**, JK Anderson, Pangan AL. Clinical and MRI Remission in Patients With Non-Radiographic Axial Spondyloarthritis Who Received Long-Term Open-Label Adalimumab Treatment: 3-Year Results of the ABILITY-1 Trial. **Arthritis Research & Therapy 2018: 20:61 (doi.org/10.1186/s13075-018-1556-5).**

26. Codreanu C, Andersone D, Baranauskaite A, Damjanov N, Dalle H, **Hojnik M**, Mann HF, Nagy O, Poór G. Application of treat-to-target principles in patients with early rheumatoid arthritis in routine clinical practice in Central-Eastern Europe. **Int J Clin Rheumatol 2018; 13: 162-71.**

27. Opris-Belinski D, Erdes SF, Grazio S, Šenolt L, **Hojnik M**, Nagy O, Marina D, Szántó S. Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries. **Drugs Context 2018; 7: 212556. doi: 10.7573/dic.212556.**

28. Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, **Hojnik M**, Nurwakagari P, Weinman J. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. **RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585.**

29. Landewé R, Ritchlin CT, Coates LC, Aletaha D, Guérette B, Zhang Y, Ganz F, **Hojnik M**. Inhibition of Radiographic Progression in Psoriatic Arthritis by Adalimumab Independent of the Control of Clinical Disease Activity. **Rheumatology (Oxford) 2019; 58: 1025-33.**

30. Deodhar A, van der Heijde D, Gensler L, Kim TH, Maksymowych WP, Ostergaards M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, **Hojnik M**, Gallo G, Zhao F, Adams D, Carlier H, Sieper J on behalf of the COAST-X Study Group. Ixekizumab treatment in patients with non-radiographic axial spondyloarthritis: results of a 52-week randomized, placebo-controlled trial. **Lancet 2020; 395: 53-64.**

31. Elewaut D, Braun J, Anderson JK, Arikan D, Chen S, **Hojnik M**, De Craemer AS, Curtis JR. Low incidence of inflammatory bowel disaese adverse events in adalimumab clinical trials across nine different diseases. **Arthritis Care Res (Hoboken) 2020; 73:289-95.**

32. Boehncke WH, Horvath R, Dalkilic E, Lima SAL, Okada M, **Hojnik M,** Ganz F, Lubrano E. Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. **J Eur Acad Dermatol Venereol 2020; 34: 2035-43.**

33. Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, **Hojnik M**, Sapin C, Okada M, Caporali R, Gratacos J, Goupille P, Liu-Leage S, Pillai S, Nash P. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. **Ann Rheum Dis 2020; 10: 1310-9.**

34. Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, **Hojnik M**, Mease PJ, Kavanaugh A; SPIRIT-P3 Study Group. Withdrawing Ixekizumab in Patients with Psoriatic Arthritis who Achieved Minimal Disease Activity: Results from a Randomized, Double-Blind Withdrawal Study. **Arthritis Rheumatol 2021; 73: 1663-72.**

35. Landewé RB, Gensler LS, Poddubnyy D, Rahman P, **Hojnik M**, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F; COAST-Y study group. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). **Ann Rheum Dis 2021; 80: 1022-30.**

36. Poddubnyy D, Sieper J, Akar S, Muñoz-Fernández S, Haibel H, **Hojnik M**, Ganz F, Inman RD. Characteristics of Patients With Axial Spondyloarthritis by Geographic Regions: PROOF Multicountry Observational Study Baseline Results. **Rheumatology (Oxford) 2021; 61: 3299-308.**

37. Maksymowych WP, Baraliakos X, Lambert RG, Landewe R, Sandoval D, Carlier H, Lisse J, Li X, **Hojnik M**, Ostergaard M. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis. **The Lancet Rheumatology 2022; 4: e626-e634. doi.org/10.1016/S2665-9913(22)00185-0.**



Maja Hojnik

Indianapolis, October 4, 2024